Overview

Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome

Status:
Enrolling by invitation

Trial end date:
2022-01-06

Target enrollment:

Participant gender:

Summary

The aim of this study is to determine the role and efficacy of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from mycelia extract of Indonesia's Ganoderma lucidum as an antioxidant and anti-inflammatory agent on cardiometabolic syndrome

Phase:

Phase 2

Details

Lead Sponsor:

University of Brawijaya

Collaborator:

PT. Sahabat Lingkungan Hidup